GNTbm's Novel Cancer Drug Gets FDA Nod for US Clinical Trials

TAIPEI, Taiwan – March 05, 2026 – Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) has secured a pivotal Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for its innovative anti-cancer agent, GNTbm-38. The approval, granted on February 28, 2026, clears the path for the Taiwanese firm to initiate Phase I clinical trials in the United States, marking a significant step in the global development of a potentially groundbreaking cancer therapy.

The upcoming study, a Phase 1a/1b open-label trial, will evaluate the safety, tolerability, and preliminary efficacy of the orally administered drug in adult patients with advanced solid tumors and relapsed or refractory peripheral T-cell lymphoma (PTCL). This milestone not only validates GNTbm's five years of intensive preclinical research but also positions the company as a noteworthy innovator on the global biopharmaceutical stage.

A Novel Mechanism: Turning 'Cold' Tumors 'Hot'

At the heart of the excitement surrounding GNTbm-38 is its unique dual-action mechanism. Described as a next-generation epigenetic immunoactivator, the drug is designed to fundamentally alter the battlefield within the body where the immune system confronts cancer.

Many tumors, particularly advanced ones, develop an ability to hide from the immune system, creating what scientists call a 'cold' tumor microenvironment (TME). This environment is characterized by a lack of cancer-fighting immune cells, such as cytotoxic T lymphocytes (CTLs), and a high concentration of immunosuppressive cells that protect the tumor. GNTbm-38 aims to reverse this by remodeling the TME and turning these 'cold' tumors 'hot'.

By acting as an epigenetic regulator—specifically, a benzamide-based class I HDAC inhibitor—GNTbm-38 can influence gene expression without altering the underlying DNA. This action is intended to make cancer cells more visible to the immune system and attract an influx of CTLs. Simultaneously, it works to reduce the presence of immunosuppressive cells, effectively dismantling the tumor's defenses and making it vulnerable to immune attack. This dual approach distinguishes GNTbm-38 from earlier epigenetic drugs, whose success in solid tumors has been limited when used as monotherapy.

Dr. Chia-Nan Chen, Chairman of GNTbm, highlighted the drug's innovative nature in a recent statement. "GNTbm-38 is a new generation anti-cancer immunotherapy drug independently developed by the GNTbm R&D team after years of experiences on developing new drug Kepida®," he stated. "GNTbm-38 has excellent epigenetic regulation and immune activation mechanisms, which can control the on-off switches of genes and further impact the expression of genes and proteins at a deeper level."

Addressing Critical Unmet Needs in Oncology

The initial clinical trial targets patient populations facing dire prognoses and limited therapeutic avenues. Peripheral T-cell lymphomas are a group of aggressive and heterogeneous non-Hodgkin lymphomas. For patients whose disease has relapsed or become refractory to standard treatments like CHOP chemotherapy, outcomes are often dismal, with low and non-durable response rates to subsequent therapies.

Similarly, patients with a wide range of advanced solid tumors often exhaust conventional treatment options and face challenges with therapeutic resistance. The development of an oral drug like GNTbm-38 offers not only a novel mechanism of action but also the potential for improved quality of life and convenience compared to intravenous therapies.

The company's strategy reflects a deep understanding of these challenges. GNTbm plans to prioritize development for relapsed or refractory PTCL to seek an orphan drug designation, a status that can accelerate development and review. Subsequently, it aims to expand into other cancer indications, leveraging the drug's broad-spectrum potential.

A Global Leap for Taiwanese Biotech

The FDA's green light is more than just a regulatory hurdle cleared; it represents a significant validation of GNTbm's research and development capabilities and a major stride for Taiwan's burgeoning biotech sector. GNTbm, which trades on the Taipei Exchange under the stock code 7427, has already demonstrated its ability to bring a drug to market with Kepida®, an anticancer treatment for advanced breast cancer launched in Taiwan.

With GNTbm-38, the company is making a calculated and ambitious move into the highly competitive U.S. and global markets. The drug's intellectual property is already secured with patents granted in 40 countries, laying the groundwork for a worldwide commercial strategy. Following the U.S. trials, GNTbm plans to collaborate with experienced contract research organizations (CROs) to launch multi-national, multi-center trials in China and Taiwan.

This progression follows a year of accolades for the drug, including a presentation of its research findings at the prestigious American Society of Clinical Oncology (ASCO) meeting in 2025 and recognition with the 22nd Taiwan National Innovation Award.

The Path Forward: Combination Therapy and Clinical Promise

The true potential of GNTbm-38 may lie in its ability to work synergistically with other treatments. The company's preclinical data suggests that its TME-remodeling effect can significantly enhance the efficacy of other powerful cancer therapies. By turning 'cold' tumors 'hot', GNTbm-38 could make previously unresponsive tumors susceptible to immune checkpoint inhibitors, multi-kinase inhibitors, and anti-PD-1/VEGF bispecific antibodies.

This opens the door to powerful combination strategies that could generate stronger, more durable anti-cancer effects. The upcoming Phase I trial will be the first crucial test of GNTbm-38's safety and activity in human patients. For individuals battling some of the most challenging forms of cancer, this trial represents a new beacon of hope and a critical step toward a potentially more effective and safer innovative treatment.